Phaseline

Companies › MoonLake Immunotherapeutics

MoonLake Immunotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Immunology, Infectious disease; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
M-1095
Interleukin 17A inhibitor; Interleukin-17F inhibitor
IL17A, IL17FPhase 3Hidradenitis Suppurativa; Arthritis, PsoriaticJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06768671M-1095Phase 3Hidradenitis SuppurativaInfectious diseaseSep 2026
NCT06641089M-1095Phase 3Arthritis, PsoriaticImmunologyJan 2027
NCT06641076M-1095Phase 3Arthritis, PsoriaticImmunologyFeb 2027

From the company's SEC filings

Cash and short-term investments of $498m on 2026-09-30; operating cash outflow about $249m a year; runway about 24 months at that burn, to Sep 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IL17A (1) IL17F (1)

Companies with the same targets

Celltrion UCB Biopharma SRL Novartis Suzhou Suncadia Biopharmaceuticals Biocad Eli Lilly Zura Bio Sinocelltech Taizhou Mabtech Pharmaceutical

Companies built like this

Zura Bio Chengdu Kangnuoxing Biopharma AnaptysBio Vor Biopharma Q32 Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.